PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.18%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-3.63%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-11.36%
Negative EBIT growth while ADI is at 7.68%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-11.36%
Negative operating income growth while ADI is at 7.68%. Joel Greenblatt would press for urgent turnaround measures.
-10.69%
Negative net income growth while ADI stands at 76.41%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-9.76%
Negative EPS growth while ADI is at 73.68%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-10.00%
Negative diluted EPS growth while ADI is at 77.78%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-1.18%
Share reduction while ADI is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.22%
Reduced diluted shares while ADI is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
1.20%
Dividend growth under 50% of ADI's 18.76%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
-38.66%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-73.49%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
19.20%
10Y revenue/share CAGR under 50% of ADI's 200.04%. Michael Burry would suspect a lasting competitive disadvantage.
47.21%
Positive 5Y CAGR while ADI is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
60.39%
3Y revenue/share CAGR above 1.5x ADI's 31.83%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
839.85%
10Y OCF/share CAGR 1.25-1.5x ADI's 615.82%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
422.47%
Positive OCF/share growth while ADI is negative. John Neff might see a comparative advantage in operational cash viability.
199.68%
3Y OCF/share CAGR above 1.5x ADI's 65.14%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
243.23%
Net income/share CAGR at 75-90% of ADI's 307.68%. Bill Ackman would press for strategic moves to boost long-term earnings.
183.91%
Positive 5Y CAGR while ADI is negative. John Neff might view this as a strong mid-term relative advantage.
427.26%
3Y net income/share CAGR above 1.5x ADI's 99.31%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
154.02%
Below 50% of ADI's 617.40%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-3.52%
Negative 5Y equity/share growth while ADI is at 42.45%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
10.46%
Below 50% of ADI's 23.75%. Michael Burry suspects a serious short-term disadvantage in building book value.
43.45%
Dividend/share CAGR of 43.45% while ADI is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
44.81%
Dividend/share CAGR of 44.81% while ADI is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
36.80%
3Y dividend/share CAGR of 36.80% while ADI is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
9.10%
Our AR growth while ADI is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-2.12%
Inventory is declining while ADI stands at 3.76%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-6.80%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-4.73%
We have a declining book value while ADI shows 0.49%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-51.89%
We’re deleveraging while ADI stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
6.60%
R&D growth drastically higher vs. ADI's 6.13%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-0.94%
We cut SG&A while ADI invests at 13.65%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.